Venetoclax (VEN) is a BCL2 inhibitor that was explored in combination with AZA as a first-line treatment for elderly AML patients in a phase III randomized trial; OS was longer in patients receiving the combination therapy than in those receiving AZA alone [19]. This evidence concerns the gene BCL2 and acute myeloid leukemia.